Tag: lung cancer treatment
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
GSK expands deal worth $ 10.6B for lung cancer treatment
GSK plc and Nuvalent, Inc. announced that they have entered into a definitive agreement under which GSK will acquire Nuvalent, a clinical-stage biopharmaceutical company focused on...